CLAIMS

What is claimed is:

1. An isolated antibody, wherein the antibody specifically binds ApoE and is derived from a hybridoma selected from the group consisting of HJ6.1 (ATCC Patent Deposit Designation PT-11805), HJ6.2 (ATCC Patent Deposit Designation PT-11806), HJ6.3 (ATCC Patent Deposit Designation PT-11807), and HJ6.4 (ATCC Patent Deposit Designation PT-11808).

2. The isolated antibody of claim 1, wherein the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, and SEQ ID NO:16.

3. The isolated antibody of claim 1, wherein the antibody is encoded by a nucleic acid sequence comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, and SEQ ID NO:15.

4. The isolated antibody of claim 1, wherein the antibody is selected from the group consisting of a single-chain antibody, an antibody fragment, a chimeric antibody, or a humanized antibody.

5. An isolated antibody, wherein the antibody specifically binds ApoE and comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:21 with zero to two amino acid substitutions.

6. An isolated antibody, wherein the antibody specifically binds ApoE and comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:27 with zero to two amino acid substitutions.

7. An isolated antibody, wherein the antibody specifically binds ApoE and comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:33 with zero to two amino acid substitutions.

8. Use of at least one anti-ApoE antibody in the manufacture of a medicament for treating at least one symptom or sign of Aß plaque associated symptoms in a subject.

9. The use of claim 8, wherein the treating includes preventing, attenuating, reversing, or improving at least one symptom or sign of Aß plaque associated symptoms in a subject.

10. The use of claim 8, wherein a symptom or sign of Aß plaque associated symptoms includes impaired cognitive function, altered behavior, abnormal language function, emotional dysregulation, seizures, impaired nervous system structure or function, and an increased risk of development of Alzheimer's disease or cerebral amyloid angiopathy.

11. The use of claim 8, wherein the anti-ApoE antibody binds an epitope within the ApoE coding sequence.

12. The use of claim 8, wherein the administration comprises an effective systemic route of administration.

13. The use of claim 8, wherein the administration comprises an effective local route of administration including directly within the central nervous system.

14. Use of at least one anti-ApoE antibody in the manufacture of a medicament for decreasing the amyloid plaque load in the brain of a subject.

15. The use of claim 14, wherein the anti-ApoE antibody binds an epitope within the ApoE coding sequence.

16. The use of claim 14, wherein the administration comprises an effective systemic route of administration.

17. The use of claim 14, wherein the administration comprises an effective local route of administration including directly within the central nervous system.

18. The use of claim 14, wherein the amyloid plaque loads are decreased in the hippocampus.

19. The use of claim 14, wherein the amyloid plaque loads are decreased in the cortex.

CLAIMS

What is claimed is:

1. Use of at least one anti-ApoE antibody in the manufacture of a medicament for reversing at least one symptom or sign of Aß plaque associated symptoms in a subject.

2. The use according to claim 1, wherein a symptom or sign of Aß plaque associated symptoms includes impaired cognitive function, altered behavior, abnormal language function, emotional dysregulation, seizures, impaired nervous system structure or function, and an increased risk of development of Alzheimer's disease or cerebral amyloid angiopathy.

3. The use according to claim 1, wherein the anti-ApoE antibody binds an epitope within the ApoE coding sequence.

4. The use according to claim 1, wherein the administration comprises an effective systemic route of administration.

5. The use according to claim 1, wherein the administration comprises an effective local route of administration including directly within the central nervous system.

6. Use of at least one anti-ApoE antibody in the manufacture of a medicament for decreasing the amyloid plaque load in the brain of a subject.

7. The use according to claim 6, wherein the anti-ApoE antibody binds an epitope within the ApoE coding sequence.

8. The use according to claim 6, wherein the administration comprises an effective systemic route of administration.

9. The use according to claim 6, wherein the administration comprises an effective local route of administration including directly within the central nervous system.

10. The use according to claim 6, wherein the amyloid plaque loads are decreased in the hippocampus.

11. The use according to claim 6, wherein the amyloid plaque loads are decreased in the cortex.